docetaxel treatment were positive for PFS ( P = .040) and marginally significant for OS ( P = .050), indicating that the presence of an ATM mutation may predict better outcomes with atezolizumab in the high bTMB subgroup (eTable 10).
11 However, a prospective, phase II, B-F1RST study only showed a trend toward a PFS benefit (hazard ratio (HR) = 0.66; 90% confidence interval (CI): 0.42–1.02; P = .12) and an OS benefit (HR = 0.77; 90% CI: 0.41–1.43; P = .48). 12 Cancer is a genetic disease, and multiple genetic mutations may lead to resistance to therapy, including immunotherapy. 13 Recent studies r